New national guidance from 11 major medical societies calls for identifying and treating high cholesterol earlier in life, with treatment potentially starting at age 30 for those at highest risk. The updated 2026 ACC/AHA Guideline on the Management of Dyslipidemia, released in March 2026, represents a significant shift in how doctors approach cardiovascular disease prevention, emphasizing that lower cholesterol exposure over a lifetime dramatically reduces heart attack and stroke risk. Why Are Doctors Starting Cholesterol Treatment Earlier? The new guidelines reflect growing evidence that intervening sooner can substantially reduce long-term cardiovascular risk. An estimated 1 in 4 U.S. adults has high levels of low-density lipoprotein cholesterol, or LDL-C, commonly called "bad" cholesterol, which increases the risk of heart attack and stroke. The key insight driving this change is that cumulative exposure to unhealthy lipids over decades matters more than doctors previously thought. "We know 80% or more of cardiovascular disease is preventable and elevated LDL cholesterol is a major part of that risk. While we want to try to optimize healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren't within the desirable range after a period of lifestyle optimization, we should consider adding lipid-lowering medication earlier than we would have considered 10 years ago," said Roger Blumenthal, MD, chair of the guideline writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. Roger Blumenthal, MD, Chair of Guideline Writing Committee, Johns Hopkins Hospital The guideline emphasizes that "lower LDL is better, especially for people at increased risk for a heart attack or stroke," and that maintaining lower cholesterol levels for longer provides much greater protection against future cardiovascular events. What's the New Tool for Assessing Your Risk? A major change in the updated guidelines is the introduction of a newer, more accurate risk calculator called PREVENT (Predicting Risk of Cardiovascular Disease EVENTs). This tool is designed for adults ages 30 to 79 without known heart disease and estimates both 10-year and 30-year risk of heart attack or stroke. The older risk calculator, the Pooled Cohort Equations, overestimated cardiovascular risk by 40% to 50%, meaning many people were either over-treated or under-treated based on inaccurate predictions. The PREVENT calculator classifies 10-year risk into four categories: low (less than 3%), borderline (3% to less than 5%), intermediate (5% to less than 10%), and high (10% or higher). These categories guide whether doctors should prescribe cholesterol-lowering medications and how intensively they should treat. Beyond basic cholesterol numbers, the new guidelines recommend considering "risk enhancers" that personalize treatment decisions. These include family history of heart disease, chronic inflammatory conditions like lupus or rheumatoid arthritis, conditions such as diabetes or chronic kidney disease, and reproductive risk markers including early menopause, preeclampsia, or gestational diabetes. How to Understand Your New Cholesterol Targets The guidelines reestablish specific LDL-C goals based on individual risk level. Understanding these targets helps you and your doctor determine whether your current treatment is adequate: - Borderline or Intermediate Risk: LDL-C goal should be less than 100 mg/dL (milligrams per deciliter) to prevent a first heart attack or stroke. - High Risk: LDL-C goal should be less than 70 mg/dL for those with diabetes, elevated 10-year risk, or other cardiovascular risk factors. - Very High Risk: LDL-C goal should be less than 55 mg/dL for individuals who have already experienced a heart attack or stroke and need secondary prevention. These lower targets represent a meaningful change from previous guidance and reflect clinical trial evidence showing that aggressive cholesterol lowering prevents more cardiovascular events. What New Tests Should You Ask Your Doctor About? The updated guidelines expand testing recommendations to give a more complete picture of cardiovascular risk. Several new or newly emphasized tests can help refine your personal risk assessment and guide treatment intensity: - Lipoprotein(a) Testing: All adults should have their lipoprotein(a), or Lp(a), measured at least once in their lifetime. Lp(a) is a type of cholesterol that increases heart disease risk but is not detected by standard cholesterol tests. High Lp(a) (125 nmol/L or greater, or 50 mg/dL or greater) is associated with about a 1.4-fold increased long-term risk of heart attack or stroke, while an Lp(a) of 250 nmol/L is associated with at least a two-fold increased risk. Because Lp(a) is largely genetically determined and stable over a lifetime, repeat testing is generally not needed. - Coronary Artery Calcium Scoring: For adults with borderline or intermediate 10-year risk who are uncertain about starting statin therapy, a non-contrast coronary artery calcium (CAC) scan can check for early cholesterol and plaque buildup in heart arteries. If any calcium is detected, statins are recommended, and lower LDL-C targets apply based on the amount of calcium present. - Apolipoprotein B Testing: ApoB may be used to assess remaining cardiovascular risk and guide treatment among people with diabetes, high triglycerides, or known cardiovascular disease who have reached their LDL-C goals. ApoB may be a more accurate risk marker than LDL-C in these specific groups. "With this new assessment tool, we can better estimate cardiovascular risk using health information already obtained during an annual physical and then further personalize the risk score for each individual by looking at 'risk enhancers,' which can help guide the need for lipid-lowering therapy," explained Roger Blumenthal. Roger Blumenthal, MD, Johns Hopkins Hospital What About Lifestyle Changes and Medications? The guidelines emphasize that lifestyle modification remains the foundation of cardiovascular disease prevention. Healthy habits include maintaining a healthy weight, engaging in regular physical activity, avoiding tobacco products, prioritizing healthy sleep, and following a heart-healthy diet. However, for many people, lifestyle changes alone are insufficient to reach cholesterol goals. When medications are needed, statins remain the cornerstone of therapy. The guidelines note that clinical trials have continued to show that lower cholesterol is better, and doctors now have multiple therapies beyond statins to lower cholesterol and prevent heart attacks and strokes. After statins, evidence-based options include ezetimibe, bempedoic acid, and PCSK9 inhibitors, which can be used for patients who need more intensive cholesterol lowering. "Clinical trials have continued to show us that lower is better, and we now have multiple therapies beyond statin drugs to lower cholesterol and prevent heart attacks and strokes. Our job now is to work to translate these guidelines to practice, to help our patients reach these evidence-based goals," stated Ann Marie Navar, MD, PhD, Associate Professor of Internal Medicine at UT Southwestern Medical Center. Ann Marie Navar, MD, PhD, Associate Professor of Internal Medicine, UT Southwestern Medical Center The shift toward earlier intervention and more personalized risk assessment represents a fundamental change in cardiovascular prevention strategy. By identifying high-risk individuals sooner and using better tools to estimate lifetime risk, doctors have a real opportunity to prevent disease rather than simply treating it after a heart attack or stroke has already occurred.
